Aligos Therapeutics, Inc. (ALGS) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending December 2025, Aligos Therapeutics, Inc. (NASDAQ:ALGS) is held by 40 institutional firms.

• The collective stake of institutional investors in Aligos Therapeutics moved to 27.1% in December 2025, a shift up from the 25.6% reported for September 2025.
• The company experienced a 23.95% quarterly change in institutional shares held, alongside an increase of 14.29% in total owners annually.
• Of these 40 institutional investors, 21 increased their holdings in Aligos Therapeutics, while 7 of them reduced positions, and 12 investors maintained their exposure.
• This class of investors increased its holdings in Aligos Therapeutics to 2.81Mn shares for the 13F-cycle ending December 2025, up by 543.18K shares quarter on quarter, and up 1.19Mn shares year over year.
• Deep Track Capital, LP continues to be the largest institutional holder of Aligos Therapeutics as of December 31, 2025, with a position of 444.11K shares, representing 4.28% of the company's outstanding stock.
• Among the most significant buyers of Aligos Therapeutics during December 2025 were MARSHALL WACE, LLP (268.66K), SummitTX Capital, L.P. (139.42K), Verition Fund Management LLC (71.25K), TWO SIGMA INVESTMENTS, LP (41.65K), CITADEL ADVISORS LLC (41.52K).
• Leading sellers of Aligos Therapeutics stock in December 2025 included Woodline Partners LP (179.03K), UBS Group AG (15.82K), MORGAN STANLEY (8.76K), WELLS FARGO & COMPANY/MN (1.67K), Tower Research Capital LLC (TRC) (418).
• The top 10 institutional holders of Aligos Therapeutics for the quarter ending December 2025 included Deep Track Capital, LP (444.11K), Alyeska Investment Group, L.P. (412.00K), Sio Capital Management, LLC (335.94K), Woodline Partners LP (289.17K), MARSHALL WACE, LLP (268.66K), VANGUARD GROUP INC (200.40K), SummitTX Capital, L.P. (139.42K), RENAISSANCE TECHNOLOGIES LLC (85.44K), BAKER BROS. ADVISORS LP (83.06K), TWO SIGMA INVESTMENTS, LP (80.65K).